



Miami Thyroid Oncology Symposium

April 9-10, 2021

Featured Workshops

Advances in Radioactive Iodine Theranostics
Advances in Molecular Diagnostics of Thyroid Nodules

Symposium Overview


We welcome you to the 4th Miami Thyroid Oncology Symposium to discuss the science and art of care of patients with thyroid nodules and cancer. The paradigm is “ Personalized Medicine” by means of “Molecular Theranostics”. Our approach to thyroid nodules and thyroid cancer has expanded beyond conventional diagnostics and therapeutic interventions. A broad catalogue of genomic and epigenomic markers associated with thyroid cancer is now available and are in clinical use. The risk stratification systems that are critical for initial surgical treatment and subsequent use of radioactive iodine treatment will rely more and more on distinct molecular markers, and less on traditional parameters. Genomics with molecular pathology and molecular imaging reflect the true biologic nature of the different cancer types currently defined by conventional morphologic features. The tumor differentiation/de-differentiation and clinical behavior for each individual cancer are now being defined by molecular characteristics, in addition to standard histopathology. The Miami Thyroid Oncology Symposium offers a platform for in depth discussions of the science of thyroid cancer diagnosis and treatment in this new paradigm. It is a unique scientific forum where practicing physicians learn how to adopt and incorporate the new treatment tools and techniques into their daily practice.

The symposium is a two-day program. There will be two half-day workshops on the first day of the symposium; *Advances in Radioactive iodine (RAI) Theranostics* and *Advances in Molecular Diagnostics of Thyroid Nodules*, which will provide in depth overview of these specific areas and address current controversies. The plenary session on the second day of the symposium on Saturday, April 10, 2021 is entitled *Frontiers in Thyroid Oncology*. This session brings together world renowned experts presenting and discussing the state of the Art in Thyroid cancer diagnosis and treatment.

The 2021 Miami Thyroid Oncology Symposium (MTOS) will be held in a virtual format due to the unprecedented times we are experiencing. We are committed to uphold the high-quality symposium standards we have built in the prior years. We are indebted to our world-renowned faculty for taking part in this exciting new scientific platform. We also hope to expand our attendance by reaching to a larger national and international audience via the virtual format.



Seza Gulec, MD, FACS
Symposium Co-Director



Yuri Nikiforov, MD, PhD
Symposium Co-Director

Symposium Faculty

Seza Gulec, MD, FACS, FACNM, Symposium Co-Director

Professor of Surgery and Nuclear Medicine, Florida International University College of Medicine
President Elect, Medical staff, Aventura Hospital and Medical Center, Miami FL
President and Chairman of the Board, Miami Cancer Research Center

Yuri E. Nikiforov, MD, PhD, Symposium Co-Director

Vice-Chair Department of Pathology, Director, Division of Molecular & Genomic Pathology
University of Pittsburgh Medical Center, Pittsburgh, PA

Marina N. Nikiforova, MD

Professor, Department of Pathology, Director, Molecular & Genomic Pathology Laboratory
University of Pittsburgh Medical Center, Pittsburgh, PA

James A. Fagin, MD

Division Head, Subspecialty Medicine, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College, New York, NY

R. Michael Tuttle, MD

Acting Chief, Endocrinology Service, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College, New York, NY

Maria Cabanillas, MD

Professor and the Faculty Director of Clinical Research
Department of Endocrine Neoplasia, MD Anderson, Houston, TX

Markus Luster, MD

Professor of Nuclear Medicine
Department of Nuclear Medicine, University Hospital Marburg, Germany

Victor J Bernet, MD

Mayo Clinic College of Medicine, Jacksonville, FL USA

Bennett Greenspan, MD, FACNP

Chairman of Advisory Board and Senior Associate Researcher
Miami Cancer Research Center, Miami, FL

Sarah Mayson, MD

Associate Professor of Medicine, Division of Endocrinology, Metabolism and Diabetes,
University of Colorado School of Medicine, Aurora, CO


Douglas Van Nostrand, MD, FACP, FACNP

Director of Nuclear Medicine at MedStar Health Research Institute
Professor of Medicine at Georgetown University Medical Center in Washington, DC

NUCLEAR ONCOLOGY WORKSHOP
Advances in Radioactive Iodine Theranostics
 Friday, April 9, 2021 | 07:30-12:00

- 08:00 **Welcome and Introduction**
Dr. Seza Gulec
- 08:00-08:30 **Molecular Basis of RAI Theranostics**
 -Brief History: Hertz, Fitzgerald, Beirwaltes, Mazafferri Trail
 -Tumor Biology and RAI Physiology: Iodine Metabolism and RAI kinetics, MAPK and TDS
Dr. Seza Gulec
- 08:30-09:00 **RAI Avidity and Responsiveness**
 -Definitions and Classifications: RAI Refractory Disease, RAI Resistant Disease, RAI Indifferent Cancer
Dr. Douglas Van Nostrand
- 09:00-09:30 **RAI Imaging Performance**
 -Brief Physics: Sensitivity/Specificity/Spatial Resolution:
 -Clinical Imaging: Comparison of Isotopes and Scanning Techniques
 -Comparison of Pre-treatment and Post-treatment Imaging
Dr. Markus Luster
- 09:30-10:00 **Improving Diagnostic and Therapeutic Profile of RAI**
 -Evaluation of Response to RAI Treatment
 -TSH stimulation
 -Clinical Trials
Dr. Douglas Van Nostrand
- 10:00-10:30 **Theranostic Power of RAI**
 -Biologic, Anatomic, Technical Challenges and Solutions
 -Modulation of MAPK Pathway
 -I-124 PET/CT Imaging and Dosimetry
Dr. Seza Gulec
- 10:30-11:00 **Break**
Please visit our Sponsors during the break by [clicking here!](#)
- 11:00-11:30 **Appropriate Use Criteria for RAI Imaging and Treatment**
 -Dosage and Protocol Selection for RAI Imaging and Therapy
 -Adverse Events from RAI: Facts and Fiction
Dr. Bennett Greenspan
- 11:30-12:00 **Thinking Differently About “DTC” in the Genomic Paradigm**
 -Redefinition of “Differentiated Thyroid Cancer”
 -Molecular Theranostics-guided RAI Imaging and Treatment
Dr. Seza Gulec
- 12:00 **Closing Remarks and Adjourn**


**all times listed above are in Eastern Time (ET)*



MOLECULAR PATHOLOGY WORKSHOP
Advances in Molecular Diagnostics of Thyroid Nodules
Friday, April 9, 2021 | 13:00-17:00

- 13:00 **Welcome and Introduction**
Dr. Yuri Nikiforov
- 13:00-13:30 **Molecular Landscape of Thyroid Nodules and Cancer**
-Genetic Landscape of Main Types of Thyroid Cancer
-Main Types of Genetic Alterations: Mutations, Gene Fusions, Copy Number Changes
Dr. Yuri Nikiforov
- 13:30-14:00 **Principles of Molecular Diagnostics of Thyroid Nodules**
-Next Generation Sequencing
-RNA Sequencing, mRNA and miRNA
-Accuracy of detecting molecular alterations
-Building a Comprehensive Diagnostic Test Platform
Dr. Marina Nikiforova
- 14:00-14:30 **The Diagnostic Performance of Molecular Tests**
-Clinical Molecular Test Portfolio
-Determination and Comparisons of Diagnostic Performances
-Understanding Molecular Test Reports
Dr. Sarah Mayson
- 14:30-15:00 **Break**
Please visit our Sponsors during the break by [clicking here!](#)
- 15:00-15:30 **New Genetic Markers for Thyroid Nodules**
-GLIS fusions, MEK1 mutations, copy number alterations and other recently discovered cancer markers
-Genetic markers of thyroid cancer risk and impact on patient management
Dr. Marina Nikiforova
- 15:30-16:00 **Genetic Markers Associated with Familial Syndromes**
-DICER1, PTEN, RET mutations and corresponding familial syndromes
Dr. Yuri Nikiforov
- 16:00-17:00 **Case Discussions/Q&A with Panelists**
-Impact of molecular markers on clinical management of patients with thyroid nodules
Drs. Seza Gulec, Sarah Mayson, Yuri Nikiforov, and Marina Nikiforova
- 17:00 **Closing Remarks and Adjourn**

**all times listed above are in Eastern Time (ET)*



PLENARY SESSION
Frontiers in Thyroid Oncology
Saturday, April 10, 2021 | 8:00 – 17:00

- 08:00 **Welcome and Introduction**
Dr. Yuri Nikiforov and Dr. Seza Gulec
- 08:00-08:40 **Genomic predictors of sensitivity and resistance to radioiodine therapy**
Dr. James Fagin
- 08:40-09:20 **Perioperative Risk Stratification in Thyroid Cancer**
Dr. R. Michael Tuttle
- 09:20-10:00 **Molecular Approaches to Perioperative Risk Stratification**
Dr. Yuri Nikiforov
- 10:00-10:40 **Thyroidectomy: Surgical, Nuclear and Molecular Insights**
Dr. Seza Gulec
- 10:40-11:00 **AM Break**
Please visit our Sponsors during the break by [clicking here!](#)
- 11:00-11:30 **Postoperative RAI Imaging and Treatment**
Dr. Victor Bernet
- 11:30-12:00 **Panel Discussion- Q&A**
Drs. James Fagin, R. Michael Tuttle, Seza Gulec, Victor Bernet, and Yuri Nikiforov
- 12:00-13:00 **Lunch Break**
Please visit our Sponsors during the lunch break by [clicking here!](#)
- 13:00-13:30 **Clinical Considerations in Remnant Ablation and Adjuvant Treatment**
Dr. Markus Luster
- 13:30-14:00 **Targeted Therapies For Thyroid Cancer: Modulation of MAPK Output**
Dr. James Fagin
- 14:00-14:30 **Targeting Gene Fusions In Thyroid Cancer**
Dr. Maria Cabanillas
- 14:30-15:00 **Radioactive Iodine Imaging and Therapy in 2021**
Dr. Douglas Van Nostrand
- 15:00-15:30 **Molecular-guided Treatment of ATC**
Dr. Maria Cabanillas
- 15:30-16:00 **PM Break**
Please visit our Sponsors during the break by [clicking here!](#)
- 16:00-17:00 **Panel Discussion- Q&A**
Drs. Markus Luster, James Fagin, Maria Cabanillas, Douglas Van Nostrand, and Seza Gulec
- 17:00 **Closing Remarks and Adjourn**

**all times listed above are in Eastern Time (ET)*

Organizing Committee

Seza Gulec, MD, FACS, FACNM, Symposium Co-Director

Professor of Surgery and Nuclear Medicine, Florida International University College of Medicine
President Elect, Medical staff, Aventura Hospital and Medical Center, Miami FL
President and Chairman of the Board, Miami Cancer Research Center

Yuri E. Nikiforov, MD, PhD, Symposium Co-Director

Vice-Chair Department of Pathology, Director, Division of Molecular & Genomic Pathology
University of Pittsburgh Medical Center, Pittsburgh, PA

J. Paul Perales-Villarreal, MD, Symposium Administrator

Chief Operating Officer,
Miami Cancer Research Center, Miami, FL

Marisabel Davalos, MEd., CIP, CHRC®, CME Coordinator

Chief Compliance Officer,
Miami Cancer Research Center, Miami, FL

Lindsey Tolino, MBA, Symposium Coordinator


Project Manager
University of Pittsburgh Medical Center Division of Molecular & Genomic Pathology

Deidra Eberle, CMP, Symposium Coordinator

Meeting Planner
American College of Surgeons

Anthony McGoron, PhD, Symposium Senior Administrator

Professor of Biomedical Engineering and Associate Dean for Academic Affairs,
Florida International University College of Engineering and Computing
Vice President, Miami Cancer Research Center, Miami, FL





Continuing Medical Education

Miami Thyroid Oncology Symposium is organized by the Miami Cancer Research Center (MCRC). MCRC is a scientific and charitable organization that performs and supports cancer research, organizes educational events and provides support for cancer care at institutional and individual levels. The mission of the MCRC is to take part in the global fight against cancer through research, education and patient care support.

The symposium will offer a maximum of 16 AMA PRA Category 1 credit(s). Physicians should only claim credit commensurate with the extent of their participation in the meeting. CME's will be awarded from the Dade County Medical Association (DCMA), which is accredited by the Accreditation Council for Continuing Medical Education (ACCME).

The Miami Dade County Medical Association (MDCMA) is the providing Joint Sponsorship for CME for the 4th Annual Miami Thyroid Oncology Symposium (MTOS). You will be required to complete evaluations for full accreditation for participating in the 4th Annual Miami Thyroid Oncology Symposium on April 9-10th, 2021. Once the symposium begins, please expect to receive email instructions on how to complete the electronic Evaluation Forms to claim CME credit for each lecture you participated in.

Please note: Each lecture has a separate evaluation link, and you are required to complete a short evaluation for each lecture you participated in.

Because these are electronic evaluations, your data will be automatically captured and delivered to the MDCMA CME office upon completion. The MDCMA will cross reference the digital data collected when you joined and left the meeting to confirm that you participated in each lecture for which you plan to claim credit(s). Once the MDCMA receives your evaluation form(s), total hour(s) completed will be reported to the CE broker (for MTOS), who will then distribute CME Certificates.

**Using the link provided, participants/attendees must complete all evaluations by April 16, 2021.
*CME certificates will not be issued for evaluations submitted after the deadline.***

SYMPOSIUM SUPPORT

(sponsorship information continues on the next page)

GOLD LEVEL

Eisai, Inc.
Jubilant Radiopharma
Sonic Healthcare USA
Thermo Fisher Scientific

SILVER LEVEL





Bayer
Ethicon

The Symposium has also been made possible by a generous Educational Grant from Eli Lilly



SYMPOSIUM SUPPORT

The Miami Cancer Research Center would like to extend their gratitude to the following companies for making this year's 4th Annual Miami Thyroid Oncology Symposium possible. Thank you for the continued supporting and helping us fulfill our commitment in furthering the science of thyroid cancer towards the new frontiers.

Gold Level

	<p>Eisai Inc. Contact: Amy Four Email: Amy_Four@eisai.com Website: https://www.EisaiOncCongresses.com/mtos</p> <p>Click here to view Eisai Inc's promotional video.</p>
	<p>Jubilant Radiopharma Contact: Suzanne Bissonnette Email: SBissonnette@jubl.com Website: www.jubilantradiopharma.com</p>
 <p>Thyroid Genomic Classifier</p>	<p>Sonic Healthcare USA Contact Email: thyroseq@sonichealthcare.com Website: www.thyroseq.com</p> <p>Click here to view Sonic Healthcare's promotional video.</p>
 <p>The world leader in serving science</p>	<p>Thermo Fisher Scientific Contact: Celia Garcia Email: celia.garcia@thermofisher.com Website: www.thermofisher.com</p> <p>Click here to view Thermo Fisher's promotional video.</p>

Silver Level

	<p>Bayer Contact: Carlos Forment and Sandy Donaldson Email: carlos.forment@bayer.com; Sandra.Donaldson@bayer.com Website: www.bayer.us</p> <p>Click here to learn more about VITRAKVI® (larotrectinib)</p>
 <p>PART OF THE <i>Johnson & Johnson</i> FAMILY OF COMPANIES</p>	<p>Ethicon Contact: Christina Bustillo Email: cbustil1@its.jnj.com Website: https://jnj.showpad-solutions.com/</p>

The Symposium has also been made possible by a generous Educational Grant from Eli Lilly